WuXi Biologics : Manufacturing & DS/DP Tech Transfer

Prasad Pasupuleti is a seasoned bioprocess development leader with over 19 years of experience in the biopharmaceutical industry, specializing in biosimilar downstream process development, technology transfer, process characterization, viral clearance, and support to regulatory submissions across global markets including the US (FDA), EU (EMA), Japan (PMDA), and ROW.

Currently serving as the Functional Leader – Downstream Process Development at Biocon Biologics Ltd, Bangalore, Prasad Pasupuleti is responsible for advancing biosimilar downstream processes, process optimization, scale-up strategies, and platform development. He also advises the company’s Center of Excellence on next-generation continuous processing and high-titer harvest strategies.

Prior to Biocon, he held the role of Associate Director-I (CMC Lead) at Viatris Ltd, where he led drug substance and drug product lifecycle management, oversaw regulatory dossier preparation, managed CDMO collaborations (WuXi, KKB, FKB, Patheon), and supported successful FDA pre-license inspections.

Previously, he worked at Intas Pharmaceuticals Ltd and Hetero Biopharma, where he led downstream development teams, contributed to multiple biosimilar programs, established pilot-scale labs, and executed technology transfers up to 2 kL scale. His earlier roles at Dr. Reddy’s Laboratories, Indus Biotherapeutics, Zenotech Laboratories, and IIT Kharagpur further enriched his foundation in protein purification, scale-up, and bioprocess innovation.

Dr. Yuan Wen is currently focused on key account business development, and served as head of MFG1, MFG4, and later Zhejiang Site (MFG20 and DP9) of Global Manufacturing in WuXi Biologics. His teams were the first in Asia to implement 4000L and 5000L single-use bioreactors in GMP and commercial manufacturing, serving global clients for products approved by FDA, EMA, and NMPA etc. Prior to his roles in MFG, he was responsible for CCPD at the Wuxi site, focusing on late phase development and process characterization. Dr. Wen is also an experienced CMC leader to support activities from IND to commercial manufacturing. Before joining WuXi Biologics, he worked at Life Technologies and Thermo Fisher Scientific in the US, with increasing technical and business responsibilities. He holds a B.S. degree in Bioengineering from Zhejiang University, and a Ph.D. degree in Chemical and Biomolecular Engineering from The Ohio State University.

Gary Khoo is the Head of CMC at Hummingbird Bioscience, where he oversees process and analytical development, as well as CMC operations and strategy for a portfolio of antibody-based therapies, including antibody-drug conjugates (ADCs). He holds a Ph.D. in Biochemical Engineering from the University of Birmingham, UK, and brings over 20 years of experience across drug development, CMC, and manufacturing. Dr. Khoo’s expertise encompasses a wide range of modalities—recombinant proteins, monoclonal antibodies, viral vectors and vaccines, and cell- and gene-therapy products—spanning all stages of the product lifecycle from IND enabling studies, BLA process validation to commercial manufacturing.

Quanmin Chen, Ph.D., Vice President and Head of Drug Product Development (DPD) at WuXi Biologics, has 20+ years of combined experience in QC, formulation, device, process development at BMS, Xencor, Astra Zenaca etc. Ph.D. from University of Tennessee Health Sciences Center and B.S. from Shanghai Jiao Tong University.